Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 1

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
The
accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the
United States of America (“ GAAP”), which assume the Company’s ongoing operations as a going concern. The Company incurred
a net comprehensive loss of $ 702,033 21,119,151

Management
intends to secure additional operating funds through equity or debt offerings. However, success in this endeavor is not guaranteed. There
are no assurances that the Company will be able to (1) attain a revenue level sufficient to generate adequate cash flow from operations
or (2) secure additional financing through private placements, public offerings, or loans necessary to support its working capital requirements.
If funds from operations and any private placements, public offerings, or loans prove insufficient, the Company will need to explore
alternative sources of working capital. No guarantee exists that such financing will be available, or if available, on terms acceptable
to the Company. Failure to obtain sufficient working capital may compel the Company to reduce or cease its operations.

Due
to uncertainties related to these issues, significant doubt persists regarding the company’s ability to continue as a going concern.
The accompanying consolidated financial statements do not include any adjustments regarding the recoverability or classification of asset
values, nor the amounts and classifications of liabilities that might arise if the Company is unable to maintain its operations.

Basic
of Presentation

The
financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this
basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has
adopted a September 30 year-end.

Principles
of Consolidation

The
consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of
Regen. Significant inter-company transactions have been eliminated.

Use
of Estimates

The
preparation of consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that
affect the amounts reported in our consolidated financial statements and the accompanying notes. Such estimates include accounts receivables,
accrued liabilities, income taxes, long-lived assets, and deferred tax valuation allowances. These estimates generally involve complex
issues and require management to make judgments, involve analysis of historical and future trends that can require extended periods of
time to resolve, and are subject to change from period to period. In all cases, actual results could differ materially from estimates.

Reverse
Stock Split

On
March